Compare BWA & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWA | MRNA |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 11.5B |
| IPO Year | 1995 | 2018 |
| Metric | BWA | MRNA |
|---|---|---|
| Price | $53.21 | $55.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 15 | 12 |
| Target Price | ★ $57.60 | $33.00 |
| AVG Volume (30 Days) | 4.2M | ★ 9.6M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 1.28 | N/A |
| Revenue | $14,316,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $0.54 | $8.28 |
| Revenue Next Year | $4.85 | $16.53 |
| P/E Ratio | $40.24 | ★ N/A |
| Revenue Growth | 1.63 | ★ 4.29 |
| 52 Week Low | $24.40 | $22.28 |
| 52 Week High | $70.08 | $59.55 |
| Indicator | BWA | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 63.68 |
| Support Level | $41.46 | $23.74 |
| Resistance Level | $70.08 | N/A |
| Average True Range (ATR) | 1.79 | 3.84 |
| MACD | -1.24 | 0.26 |
| Stochastic Oscillator | 18.45 | 69.97 |
BorgWarner is a tier one supplier of turbo and thermal management technologies, drivetrain systems, powerdrive systems, and battery and charging systems mostly to automotive original equipment manufacturers. Its products aim to move a vehicle with as few electrons as possible, resulting in cleaner, cost-optimized, and more-efficient vehicles. Foundational products, the combustion vehicle business, contributes more than 80% to group revenue while BorgWarner transitions to becoming an electric vehicle-centric parts supplier (e-business). In 2024, 23% of the company's revenue was sourced from Volkswagen and Ford. Revenue is well diversified geographically, with approximately a third each generated in North America, Europe, and Asia.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.